Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. 

The company principally offers Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. 

Its other clinical product candidates include ABI-008, a phase II solvent-free and Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a phase I nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity; and Coroxane, a phase II nanometer-sized paclitaxel for coronary restenosis and peripheral artery restenosis. Abraxis BioScience has strategic relationships with Taiho Pharmaceutical Co., Ltd.; Biocon Limited; Green Cross Corporation; Specialised Therapeutics of Australia, Pty Ltd.; and ProMetic Life Sciences Inc. 

The company was formerly known as New Abraxis, Inc. and changed its name to Abraxis BioScience, Inc. in November 2007. Abraxis BioScience, Inc. is based in Los Angeles, California.

In 2010, Abraxis BioScience was acquired by [Celgene Corp](/company/celgene).